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A B S T R A C T
Background and aims: Apolipoprotein A-I (apoA-I) infusions represent a potential novel therapeutic approach for
the prevention of coronary artery disease (CAD). Although circulating apoA-I concentrations inversely associate
with risk of CAD, the evidence base of this representing a causal relationship is lacking. The aim was to assess the
causal role of apoA-I using human genetics.
Methods: We identified a variant (rs12225230) in APOA1 locus that associated with circulating apoA-I con-
centrations (p < 5 × 10−8) in 20,370 Finnish participants, and meta-analyzed our data with a previous GWAS
of apoA-I. We obtained genetic estimates of CAD from UK Biobank and CARDIoGRAMplusC4D (totaling 122,733
CAD cases) and conducted a two-sample Mendelian randomization analysis. We compared our genetic findings
to observational associations of apoA-I with risk of CAD in 918 incident CAD cases among 11,535 individuals
from population-based prospective cohorts.
Results: ApoA-I was associated with a lower risk of CAD in observational analyses (HR 0.81; 95%CI: 0.75, 0.88;
per 1-SD higher apoA-I), with the association showing a dose-response relationship. Rs12225230 associated with
apoA-I concentrations (per-C allele beta 0.076 SD; SE: 0.013; p = 1.5 × 10−9) but not with confounders. In
Mendelian randomization analyses, apoA-I was not related to risk of CAD (OR 1.13; 95%CI: 0.98,1.30 per 1-SD
higher apoA-I), which was different from the observational association. Similar findings were observed using an
independent ABCA1 variant in sensitivity analysis.
Conclusions: Genetic evidence fails to support a cardioprotective role for apoA-I. This is in line with the cu-
mulative evidence showing that HDL-related phenotypes are unlikely to have a protective role in CAD.
1. Introduction
Large-scale cardiovascular outcome trials [1–4] and studies of
human genetics [5] do not support a causal role of high-density lipo-
protein (HDL) cholesterol in coronary artery disease (CAD). However, it
remains feasible that other aspects of HDL, such as the functional at-
tributes of HDL particles, might have atheroprotective effects. The
ability of HDL particles to extract cholesterol from lipid-laden cells, so-
called cholesterol efflux, has recently emerged as the most prominent
new measure for HDL-related atheroprotectivity [6]. Apolipoprotein A-I
(apoA-I) is a key functional apolipoprotein component of HDL particles
and plays a central role in cholesterol efflux [7].This has led to an-
ticipation that modification of circulating apoA-I might represent a
novel therapeutic approach to the treatment and prevention of CAD.
Notably, Pfizer reportedly paid over 1bn USD for the commercial rights
for an apoA-I infusion technology [8].
Although epidemiological studies have shown that circulating con-
centrations of apoA-I are strongly inversely associated with CAD [9],
recent phase II randomized controlled trials (RCTs) that used MDCO-
216 (recombinant apoA-I Milano) and CER-001 (recombinant wild-type
apoA-I) infusions failed to identify a beneficial effect of apoA-I infusion
on the regression of coronary atherosclerosis as measured by in-
travascular ultrasonography [10,11], resulting in the termination of the
development of these apoA-I products. Regardless of these failures, a
third apoA-I infusion therapy, CSL112, representing a reconstituted
form of native apoA-I from human plasma, is currently underway in a
large phase III RCT (AEGIS-II; ClinicalTrials.gov Identifier:
NCT03473223), which seeks to assess the efficacy of CSL112 on the risk
of cardiovascular events [12,13]. Prior trials have shown CSL112 to be
well-tolerated [14,15], and capable of increasing HDL cholesterol efflux
in both healthy individuals and CAD patients [16–18].
Despite the ongoing apoA-I trial, robust evidence of ather-
oprotective properties of apoA-I is lacking. Human genetics can yield
reliable evidence on the likely efficacy of pharmacological modification
of a therapeutic target on risk of disease. For example, genetic variants
in HMGCR and PCSK9 reliably elucidate the effects of statins and PCSK9
inhibition on circulating metabolic markers (including lipoproteins and
their accompanying lipids) and risk of CAD [19,20]. In a recent study,
Richardson et al. [21] used the UK Biobank data to construct multi-
marker genetic instruments for plasma lipid traits (including apoA-I and
HDL cholesterol) to assess their causal roles in CAD using univariable
and multivariable Mendelian randomization (MR) analyses. Although
the univariable MR approach suggested that apoA-I and HDL choles-
terol might be protective of CAD, the findings diminished to the null in
multivariable analysis taking apolipoprotein B (apoB) into account.
These findings call attention on the overall validity of genetic instru-
ments in MR analyses for highly correlated lipoprotein-related mea-
sures, such as apoA-I. There is a high likelihood for horizontal pleio-
tropy through various biological pathways and mechanisms when
multiple variants are selected from across the genome. In the current
study, we used human genetics in five population-based cohorts with
detailed lipoprotein profiling together with large-scale genome-wide
data to identify a robust genetic instrument for apoA-I concentrations in
order to provide reliable estimates of the potential causal effects of
apoA-I on risk of CAD. In an effort to overcome the potential issue of
horizontal pleiotropy, we aimed to construct an instrument that would
be as free as possible from confounding and therefore our primary focus
was on the locus containing the gene encoding apoA-I. We also com-
pared our genetic results to observational associations of apoA-I con-
centrations and the risk of incident CAD in population-based cohorts.
2. Materials and methods
A diagram showing our primary approach to assess causality of
circulating apoA-I concentrations in CAD is shown in Supplemental Fig.
S1. We used individual participant data including genotyping and li-
poprotein profiling from five Finnish population-based cohorts, totaling
up to 20,370 individuals. Please see Supplementary Material for de-
tailed descriptions of the cohorts (Supplemental Text S1, S2 and S3;
Supplemental Tables S1 and S2), details of analyses (Supplemental Text
S4 and S5), and assessment of observational estimates for CAD
(Supplemental Text S6).
2.1. Identifying genetic instruments for the circulating apoA-I concentration
Our aim was to develop a genetic instrument that would mimic the
effect of apoA-I infusion therapies; i.e. we aimed to find genetic variants
that would be associated with increased circulating apoA-I concentra-
tions without being confounded by associations with lipid traits and
phenotypes, other than those that would be expected due to vertical
pleiotropy. To this end, we focused on cis-acting protein quantitative
trait loci (pQTL) in the APOA1 locus, which contains the gene encoding
apoA-I. We used this approach, because apoA-I associated variants from
the apoA-I encoding locus represent the instruments plausibly least
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likely to violate the exclusion restriction criterion, being plausibly
linked to apoA-I concentrations through cis-effects. We also investigated
whether construction of a multiallelic instrument including all cis and
trans pQTLs from loci associated with apoA-I would be feasible in our
cohorts. We investigated the effects of previously reported apoA-I as-
sociated SNPs across a wide range of lipoprotein lipids and metabolites
(Supplemental Table S3) and detected that construction of such an in-
strument was not possible due to pleiotropy across multiple lipoprotein
measures including apoB (i.e., most apoA-I associated SNPs had con-
founding associations with several lipoprotein lipids; see Supplemental
Text S7 and Supplemental Figs. S2, S3, and S4 for details). However,
one of the apoA-I associated variants (rs2740486 in ABCA1 locus) was
not associated with apoB-related cholesterol measures and was used in
sensitivity analysis to validate the associations of the cis-pQTL instru-
ment (see Supplemental Text S7 and S8). We primarily concentrated on
the 1-Mb region flanking the APOA1 gene to find genetic variants as-
sociated with circulating apoA-I concentrations. Our initial approach
was to count the number of single-nucleotide polymorphisms (SNPs) in
this region and use this value to correct the multiple testing through a
conventional Bonferroni approach, which corresponded to 7,210 SNPs
and a Bonferroni-adjusted p-value of< 7 × 10−6. However, the top
SNPs superseded this threshold and associated with apoA-I concentra-
tions at conventional levels of GWAS significance (p < 5× 10−8). We
compared our results to those of a previous GWAS of apoA-I [22] and
prioritized variant rs12225230 as the genetic instrument for apoA-I;
this SNP was reported to be associated with apoA-I concentrations in
the previous GWAS [22] and summary statistics were available from
this study. To identify whether more than one cis-pQTL associated with
apoA-I, we repeated the analysis of apoA-I concentrations on SNPs in/
around APOA1 after conditioning on rs12225230. No additional con-
ditionally-independent cis-pQTLs were identified. Details of the ana-
lyses, selection criteria, and consideration of validity of our instrument
are described in Supplementary Material (Supplemental Text S7,
Supplemental Table S4).
2.2. Assessing causality
We assessed causality between the exposure (circulating apoA-I
concentrations) and outcome (CAD) utilizing the Mendelian randomi-
zation (MR) framework (Supplemental Fig. S1). We used a two-sample
MR approach where summary data of the exposure (i.e., SNP to apoA-I
concentration) and outcome (i.e., SNP to CAD) originate from different
sources [23,24]. Rs12225230 located in the APOA1 locus was used as
the genetic instrument. This approach included the use of the following
estimates [1]: per-allele effect estimate (in g/L) for the association
between rs12225230 and apoA-I (meta-analyzed result between the
Finnish individual participant data and a prior GWAS [22]; total
N = 37,093) [2]; per-allele effect estimates with risk of CAD from a
large GWAS, i.e., meta-analysis of the UK Biobank with CARDIo-
GRAMplusC4D [25] (case N = 122,733). To obtain a causal estimate
and the corresponding standard error for the association between apoA-
I and CAD, we used the inverse-variance weighted method [26] that
collapses to Wald ratio for a single variant. To facilitate comparison
with observational estimates, the causal estimate of apoA-I concentra-
tions on risk of CAD was scaled to SD units, using SD of 0.225 g/L (the
SD of apoA-I in our largest cohort, FINRISK97). We assessed evidence of
heterogeneity between the causal and observational estimates using
Cochrane's Q statistic. In sensitivity analyses, we repeated the MR
analysis using the per-allele effect estimate between rs12225230 and
apoA-I using values derived from just the Finnish population cohorts
and just the prior GWAS [22]. We also repeated the MR analysis using
another unconfounded apoA-I associated SNP (rs2740486 in ABCA1
locus) as an instrument as a sensitivity analysis (see Supplemental Text
S7 and S8). Similar to analysis with rs12225230 as the instrument, we
used the meta-analyzed result of rs2740486 between the Finnish in-
dividual participant data and a prior GWAS [22] in this analysis.
Finally, we created an instrument using both rs12225230 and
rs2740486 and repeated the MR analysis using the inverse-variance
weighted method [26]. We report our power to detect various effect
estimates of apoA-I concentrations and risk of CAD in the MR analyses
in Supplemental Table S4.
3. Results
3.1. Identification of genetic variants associated with circulating apoA-I
concentrations
Multiple SNPs in/around the APOA1 locus were associated with
apoA-I serum concentration (Fig. 1, Supplemental Table S5) with the
association peak spanning a 466-kb region. We identified rs12225230
to associate with apoA-I concentrations at GWAS significance (per-al-
lele beta 0.076 SD, p = 1.5 × 10−9), which was in linkage dis-
equilibrium (LD) with the top SNP rs625145 (D’ = 1.00, r2 = 0.91).
This variant was previously shown to be associated with apoA-I serum
concentration [22] and is mapped to the SIK family kinase gene (SIK3)
encoding serine/threonine protein kinase SIK3, located 20 kb upstream
of APOA1. When we conditioned on rs12225230, there were no addi-
tional associations (Supplemental Fig. S5), indicating that rs12225230
or SNPs in LD with this SNP are likely the principal drivers of the apoA-I
association in this locus. We estimated the effect of the minor allele of
rs12225230 on apoA-I concentrations to be 0.0158 g/L (SE 0.0030). In
meta-analysis of our cohorts with a previous GWAS of apoA-I con-
centrations (reporting 0.0320 g/L [SE 0.0033] increment per minor
allele of rs12225230) [22] the effect of the minor allele C of
rs12225230 was estimated to be 0.0230 g/L (SE 0.0022;
p = 1.5 × 10−25), corresponding to an F-statistic of 109. We further
investigated whether any SNPs located in the APOA1 gene were asso-
ciated with apoA-I, and found that a single SNP, rs670 located in the 5′
untranslated region of APOA1 that was also previously shown to be
associated with apoA-I concentrations [27], associated with apoA-I
concentrations (per-allele beta 0.070 SD, p = 3.8 × 10−8;
Supplemental Table S5); however, this SNP is in LD (D’ = 0.90,
r2 = 0.81) with rs12225230 and thus likely represents the same asso-
ciation signal.
We assessed whether rs12225230 represents an unbiased instru-
ment to mimic the effect of apoA-I increasing therapies by character-
izing the effects of rs12225230 on metabolic measures (Fig. 2,
Supplemental Fig. S3). We detected that, in addition to associating with
higher apoA-I concentrations, the minor allele of rs12225230 was as-
sociated with higher levels of multiple HDL-related measures, in-
cluding, e.g., concentration of large, medium and small HDL particles
(L-HDL-P, beta 0.055 SD, p = 1.2E-05; M-HDL-P, beta 0.061 SD,
p = 1.2E-06; S-HDL-P, beta 0.055 SD, p = 1.2E-05), and HDL choles-
terol (beta 0.070 SD, p = 2.5E-08). In addition, rs12225230 was as-
sociated, e.g., with fatty acid measurements (e.g., polyunsaturated fatty
acids, beta 0.048 SD, p = 1.2E-04); associations with the fatty acids
likely reflect their associations with multiple HDL-related traits. In
contrast, rs12225230 was not associated with the majority of apoB
related traits (Supplemental Fig. S3). Rs12225230 showed the strongest
associations with apoA-I; associations with the other traits were weak
or null. Because our aim was to develop an instrument mimicking apoA-
I infusion therapy (and treatment with such is recognized to cause an
increase in both apoA-I and HDL cholesterol concentrations [15]), as-
sociations of our genetic instrument with HDL-C related traits should
not represent confounding in this setting. Thus, rs12225230 likely re-
presents an unbiased instrument for apoA-I concentrations. We esti-
mated that the proportion of variance in apoA-I concentrations ex-
plained by rs12225230 was 0.32%. We further estimated that we had
adequate (> 90%) power to detect an effect estimate of OR 0.80 for
CAD using rs12225230 as the genetic instrument (Supplemental Table
S4). Further considerations of validity of the instrument are given in
Supplemental Text S7.
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We further investigated whether the association of rs12225230 with
apoA-I concentration could be confounded by associations with other
phenotypes. To this end, we screened publicly available genotype-
phenotype associations (altogether 2,991 diseases and traits in a phe-
nome-wide association analysis) using PhenoScanner [28]. The asso-
ciations of rs12225230 were not likely confounded by associations with
other phenotypes, including conventional risk factors (type 2 diabetes,
systolic blood pressure, BMI, smoking, or alcohol consumption; see
Supplemental Text S7, Supplemental Table S6, Supplemental Fig. S6).
In sensitivity analysis, we used an unconfounded SNP (rs2740486) from
another apoA-I associated locus, ABCA1, as the instrument. Similar to
rs12225230, we verified that this SNP was unlikely to be confounded
through associations with other traits (see Supplemental Text S7 and
S8, Supplemental Fig. S4).
3.2. Observational associations of apoA-I concentrations with incident
coronary artery disease
We estimated the prospective observational associations of apoA-I
concentrations with risk of CAD in the FINRISK97 cohort (N = 7,133,
with 743 incident CAD events), and compared the association of apoA-I
to the corresponding CAD associations for apoB, HDL and LDL choles-
terol. In the comparisons of the lipid measures, the associations were
assessed using two models: a minimal model (age and sex as covariates)
and a fully adjusted model in which conventional risk factors for CAD
(age, sex, body mass index, systolic blood pressure, type 2 diabetes,
smoking and alcohol consumption) were included as covariates. ApoA-I
concentrations (HR 0.86 per 1-SD higher apoA-I; 95%CI 0.79–0.93,
Fig. 3) had a similar magnitude of association with CAD as did HDL
cholesterol (HR 0.79 per 1-SD higher HDL-C; 95%CI 0.72–0.86), apoB
(HR 0.84 per 1-SD lower apoB; 95%CI 0.79–0.91) and LDL cholesterol
(HR 0.88 per 1-SD lower LDL-C; 95%CI 0.82–0.95). The associations
were similar in minimally and fully adjusted models (Supplemental
Table S7). The association of apoA-I concentrations with CAD showed a
dose-response relationship, with the risk of CAD being HR 0.57 (95%CI
0.45–0.75) comparing the highest to lowest quintiles of apoA-I
(Fig. 3B), adjusted for the covariates in the fully adjusted model above
together with LDL cholesterol.
In meta-analysis of the FINRISK97 and FINRISK07 cohorts (total
918 incident CAD cases), higher concentrations of apoA-I associated
with a lower risk of CAD (HR 0.81 per 1-SD higher apoA-I, 95%CI
0.75–0.88) after adjustment for age, sex, and conventional risk factors
Fig. 2. Association of rs12225230 with
key lipoprotein-related concentration
measures.
Remnant cholesterol refers to choles-
terol carried in VLDL and IDL particles.
Effect sizes are estimated as SD differ-
ences in metabolite concentrations per
rs12225230-C allele. Closed symbols,
p < 0.002 (significant association);
open symbols P ≥ 0.002.
Abbreviations: apoA-I, apolipoprotein
A-I; apoB, apolipoprotein B; VLDL, very
low-density lipoprotein, LDL, low-den-
sity lipoprotein; HDL, high-density li-
poprotein; IDL, intermediate-density
lipoprotein.
Fig. 1. Association of SNPs in the
APOA1 locus with circulating con-
centrations of apoA-I.
Each dot represents the association of a
single genetic variant with apoA-I con-
centrations in meta-analysis of five
Finnish population cohorts (-log10 of p
value shown on the y axis and chro-
mosomal position on the x axis). The
500-kb region flanking APOA1 is
shown. Rs12225230 (highlighted in
violet; used as an instrument in this
study) is robustly associated with apoA-
I concentrations (p= 2× 10−9) and is
in LD with the top variant rs625145
(p= 6× 10−10). Colors of the variants
refer to their r2 values with rs12225230
in the European population.
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for CAD (LDL cholesterol, body-mass index, systolic blood pressure,
type 2 diabetes, smoking and alcohol consumption). The associations
were similar in minimally (age and sex as covariates) and fully (age,
sex, LDL cholesterol, body-mass index, systolic blood pressure, type 2
diabetes, smoking and alcohol consumption as covariates) adjusted
models and in both cohorts (Supplemental Fig. S7). ApoA-I concentra-
tions showed only low correlation (r between −0.3 and 0.3) with the
potential confounders included as covariates in the models
(Supplemental Fig. S8).
3.3. Evaluation of the causal role of serum apoA-I concentrations in
coronary artery disease
Using data from a large GWAS of coronary artery disease including
122,733 CAD cases in 547,261 individuals (meta-analysis of UK
Biobank CAD GWAS with CARDIoGRAMplusC4D [25]), rs12225230
was not associated with risk of CAD (per-allele log-odds 0.0124, SE
0.0073, p= 0.090). Similarly, no significant association of rs12225230
was reported in any of the large GWAS for cardiovascular phenotypes,
including CAD, MI or stroke (Supplemental Table S8). Rs670, located in
5’ untranslated region of APOA1, was not associated with CAD either
(per T-allele log-odds 0.0171, SE 0.0077, p = 0.025).
Using the rs12225230-apoA-I and rs12225230-CAD associations,
we did not find evidence to support a causal role of apoA-I con-
centrations with risk of CAD: the causal estimate (calculated based on
meta-analysis of our own GWAS and a previous GWAS of apoA-I [22])
for CAD was an OR of 1.13 per 1-SD higher apoA-I concentration,
95%CI 0.98–1.30 (Fig. 4, Supplemental Fig. S9) which differed (p-het-
erogeneity< 0.001) to the corresponding fully-adjusted (age, sex, LDL
cholesterol, body-mass index, systolic blood pressure, type 2 diabetes,
smoking and alcohol consumption as covariates) observational estimate
(HR 0.81; 95%CI: 0.75–0.88). Causal estimates for CAD were similar
when calculated based on the apoA-I effect estimates from the previous
GWAS [22] (OR 1.09, 95%CI 0.99–1.21) and our own GWAS (OR 1.19,
95%CI 0.97–1.46). Similarly, there was no evidence of apoA-I con-
centrations having a causal role in MI (OR 1.19, 95%CI 0.93–1.53) or
stroke (OR 0.87, 95%CI 0.70–1.07).
All of the above analyses were also conducted using an un-
confounded apoA-I associated variant from another locus (rs2740486 in
ABCA1). Similarly to rs12225230, this SNP was not associated with
CAD (per T-allele log-odds 0.0049, SE 0.0051, p = 0.343) in meta-
analysis of UK Biobank CAD GWAS with CARDIoGRAMplusC4D [25],
and there was no evidence supporting a causal role of apoA-I con-
centrations with risk of CAD (causal estimate being an OR of 1.08 per 1-
SD higher apoA-I concentration, 95%CI 0.92–1.27, p-hetero-
geneity = 0.002, Supplemental Fig. S10). Finally, we repeated the MR
analysis utilizing an instrument consisting of APOA1-rs12225230 and
ABCA1-rs2740486: the causal estimate for CAD was an OR 1.11 (95%CI
1.00–1.23, p = 0.056, p-heterogeneity< 0.001, Supplemental Fig.
S10).
4. Discussion
Our findings do not provide genetic support for the hypothesis that
circulating apoA-I concentrations are protective of CAD. Together with
previous evidence indicating that HDL cholesterol does not have a
protective effect on risk of CAD [1,2,5], these results suggest that apoA-
I may not represent a valid therapeutic approach for the prevention and
treatment of CAD.
HDL cholesterol and apoA-I are among the serum lipoprotein mea-
sures showing strongest inverse associations with cardiovascular dis-
ease in epidemiological studies [9]. However, RCTs using HDL choles-
terol increasing therapies have failed to identify that the risk of CAD is
proportionate to the amount by which HDL cholesterol is increased
[1,2] and, consistently, studies of human genetics find that the asso-
ciation of HDL cholesterol with CAD is not causal [5]. In the REVEAL
trial of the cholesteryl ester transfer protein (CETP) inhibitor, anace-
trapib, although treatment with anacetrapib did increase HDL choles-
terol, the cardiovascular benefit was proportionate to the degree of
apoB lowering, rather than to the effect on HDL cholesterol [3]. Here,
we add further evidence showing that targeting HDL-related pathways
through increases in apoA-I may not effectively lower risk of CAD. We
show that long-term genetically increased circulating apoA-I con-
centrations do not protect from CAD, a finding consistent with the
outcomes in two trials of apoA-I infusion products (MDCO-216 and
CER-001) that led to the termination of development of those products
[10,11]. Thus, randomized evidence of both the short-term, transient
increase in circulating concentration of apoA-I arising from apoA-I in-
fusions and the life-long increase caused by genetic variants fails to
support a protective role of apoA-I concentrations in CAD.
This study has several strengths. The SNP used to mimic the effect of
apoA-I-increasing therapy, rs12225230, was identified in a locus-spe-
cific analysis of SNPs in/around APOA1 in five Finnish cohorts, re-
plicating the finding of a prior GWAS [22]. By focusing on cis-acting
pQTL SNPs from the APOA1 locus, we sought to minimize the potential
Fig. 3. Observational associations of apoA-I
concentrations and risk of coronary artery
disease.
(A) The association of apoA-I concentra-
tions with CAD risk was compared to those
of key lipoprotein measures (apoB, HDL and
LDL cholesterol). Note, the effects of apoB
and LDL cholesterol are inversed; i.e., the
effects are shown per 1-SD reduction in
apoB and LDL cholesterol. Associations were assessed with 743 cases and 6,390 controls in FINRISK97, with adjustment for age, sex, body-mass index, systolic blood
pressure, type 2 diabetes, smoking and alcohol consumption. Associations are presented as HR (95%CI) per 1-SD lipoprotein measure. (B) Dose-response association
of apoA-I concentrations with risk of CAD. Associations were additionally adjusted for LDL cholesterol. Effect estimates are presented per quintile of apoA-I with the
lowest quintile (Q1) used as the reference category.
Fig. 4. Observational and causal effects of circulating apoA-I concentrations
and risk of coronary artery disease.
Observational estimate was assessed in the FINRISK97 and FINRISK07 cohorts
(918 coronary artery disease cases among 15,353 individuals) with age, sex,
LDL cholesterol, body-mass index, systolic blood pressure, type 2 diabetes,
smoking and alcohol consumption as covariates. Causal estimate was calculated
based on association of rs12225230 with apoA-I concentrations (effect estimate
from meta-analysis of five Finnish cohorts and a previous GWAS [22], total N=
37,0930) and coronary artery disease (effect estimate from meta-analysis of the
UK Biobank and CARDIoGRAMplusC4D; 122,733 CAD cases among 547,261
individuals). Effect estimates correspond to the risk (observational association:
hazard ratio, HR; causal estimate: odds ratio, OR) of CAD per 1-SD higher apoA-
I (equivalent to 0.225 g/L apoA-I).
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for confounding by trans-acting variants [24]. We recognize, however,
that the SNP, while being located within 20 kb of the APOA1 gene and
therefore qualifying as a ‘cis-pQTL’, is nonetheless annotated as a mis-
sense variant in a gene (SIK3) discrete to that which encodes apoA-I
(APOA1). There therefore remains the possibility of confounding
through functional attributes of the rs12225230 variant mediated
through SIK3. However, SIK3 has been shown to be involved in skele-
togenesis [29], and therefore it is unlikely that a skeletal developmental
gene would confound the associations. To investigate this in greater
detail, we assessed the effects of rs12225230 on a detailed panel of
serum metabolic measures as a means of providing evidence against
potential confounding by circulating metabolic markers other than
those related to HDL pathways, and supplemented this by examining
potential phenotype associations. We also repeated the MR analysis
using an apoA-I associated variant from another locus (ABCA1) and the
results were consistent. ABCA1 encodes ATP-binding cassette sub-fa-
mily member 1, a protein involved in the transport of various molecules
across membranes; of note, ABCA1 actively mediates cholesterol efflux
and therefore has particular relevance to our question of whether apoA-
I, acting to promote cholesterol efflux, leads to a reduction in risk of
CHD [30]. The stronger two-SNP instrument showed clear deviation
from the observational estimate. For all analyses, we utilized large,
well-characterized Finnish population cohorts and the largest available
international GWAS consortia data for CAD to maximize statistical
power. Taken together, our statistical and genetic approach yielded
reliable estimates of the causal effect of apoA-I on risk of CAD and fa-
cilitated the discovery that, unlike the observational association, which
is vulnerable to confounding and bias, apoA-I is unlikely to play a
causal role in CAD.
Importantly, our results indicating no causal role for apoA-I con-
centrations in CAD are in line with the results of a recent large multi-
variable MR study performed using the UK BioBank data. In this study,
Richardson et al. [21] first performed univariable MR analysis using a
multi-SNP instrument consisting of> 400 independent apoA-I asso-
ciated SNPs, which indicated a potential causal role for apoA-I in
lowering the risk of CAD. However, the authors identified that a large
proportion of the SNPs included in the apoA-I instrument were asso-
ciated with other lipid traits and were thus likely widely affected by
horizontal pleiotropy. As an example, their instrument for apoA-I
concentrations showed inverse associations with apoB and triglycer-
ides. To overcome this problem, they performed multivariable MR
taking into account the effects of apoB; these analyses resulted in a
conclusion that apoB, but not apoA-I (or HDL cholesterol), is causally
associated with CAD. Our approach, in which we used a cis-instrument
for apoA-I (a SNP from the apoA-I encoding locus that was not asso-
ciated with apoB-related lipid traits), is in agreement with the multi-
variable MR result for apoA-I.
The main focus of investigation was to provide genetic evidence on
the hypothesis of whether apoA-I infusions protect from CAD, and to do
so, we developed a genetic instrument that strongly and specifically
associates with circulating apoA-I concentrations. However, the ratio-
nale behind apoA-I-infusion therapies is that increases in apoA-I ought
to promote cholesterol efflux from arterial wall macrophages, a process
that can be quantitatively measured by HDL cholesterol efflux capacity
(HDL-CEC). Similar to HDL cholesterol and apoA-I, HDL-CEC is in-
versely associated with risk of CAD [6]. The AEGIS trial showed that
apoA-I infusion therapy with CSL112 led to higher concentrations of
apoA-I and higher HDL-CEC [15,18], which suggests that higher HDL-
CEC may represent a target-mediated effect of elevations in apoA-I. If
this were true, then we would expect that our genetic instrument for
higher apoA-I concentrations would also lead to higher HDL-CEC.
Therefore, we would expect that any effect of apoA-I infusion therapy
on HDL-CEC ought to be represented by our genetic instrument. Of
note, the neutral association in Mendelian randomization of the apoA-I
associated ABCA1 variant with CAD provides important evidence which
potentially speaks to a non-causal role of HDL-CEC. Furthermore, in
addition to our findings, studies have indicated that either rare or
common variants in the APOA1 (associated with apoA-I concentrations)
and ABCA1 (associated with HDL cholesterol) genes are not associated
with cardiovascular disease [27,31].
Taken together, multiple lines of evidence (including our MR results
for apoA-I) clearly indicate that HDL cholesterol and apoA-I are likely
not to have atheroprotective effects [1–5,21,32]. Future studies will
show if the same is also true for HDL-CEC; indeed, some studies have
suggested that cholesterol efflux capacity may associate with cardio-
vascular disease independent of HDL cholesterol and apoA-I [33]. In
addition, it should be noted that despite the findings in human studies,
several animal studies have suggested that apoA-I could be a causal
atheroprotective factor [34–36]. However, although the first apoA-I
trial indicated that apoA-I Milano/phospholipid complex infusions may
regress coronary atherosclerosis [37], subsequent RCTs including the
recently terminated MDCO-216 and CER-001 trials [10,11] have failed
to find a beneficial effect of apoA-I infusions, which, together with our
results, strongly indicate a non-causal role for apoA-I in humans.
A common criticism of drug-target Mendelian randomization ana-
lyses is that the genetic association with the biomarker of interest (in
this case apoA-I) is typically small, and thus meaningful deductions
cannot be made about the likely impact of modifying apoA-I through a
therapeutic (such as an infusion), where the effect of the intervention
on the biomarker of interest is typically much larger. The counter-
argument is that atherosclerosis is a life-long disease, and exposure to a
small but consistent genetic elevation in apoA-I over several decades
ought to lead to a lower risk of vascular disease if apoA-I is truly car-
dioprotective. It is this ‘cumulative’ exposure in the setting of a disease
with a long latency period (such as cardiovascular disease) which
means that ‘physiological’ risk factors such as LDL cholesterol tend to
have much larger effects on risk of cardiovascular disease from
Mendelian randomization than from conventional observational studies
[24]. In our study, we had good power (> 90%) to detect an effect
estimate from Mendelian randomization which was similar to that
which we identified from our observational analyses. A false negative
might arise were there to be a physiological threshold above which
apoA-I is cardioprotective but below which it has no effect. To in-
vestigate the plausibility of such a threshold effect, our observational
analyses, in which we generated quintiles based on measured values of
apoA-I concentrations, showed a clear dose-response relationship be-
tween apoA-I concentrations and risk of vascular disease, which argues
against such a threshold effect.
This study provides an example of using human genetics to guide
the development of therapeutic targets and predict the effects of phase
III cardiovascular outcome trials [38]. We note the similarity to other
‘negative’ MR studies of secretory phospholipase IIA-A2 [39] and Lp-
PLA2 [40], both of which were the focus of large-scale phase III car-
diovascular outcome trials. The cumulative evidence, including genetic
evidence from the recent multivariable MR study of lipid traits [21] and
our study, brings into question whether pharmaceutical research and
development should continue to invest in developing apoA-I infusion
therapies for preventing CAD.
In conclusion, our findings do not support the hypothesis that in-
creasing circulating apoA-I concentrations represents a valid approach
for the prevention of CAD. These results add to the burgeoning evidence
that refutes a protective role of HDL and HDL-related phenotypes in the
etiology of CAD.
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